Pharmaxis : R&D Showcase Presentations Webinar 1

R&D Showcase Webinars

Pharmaxis drug PXS-5505 targeting several cancers

Investor Presentation | 29 March 2022

developing breakthrough treatments for fibrosis and inflammation

Forward looking statement

This document contains forward-looking statements, including statements concerning Pharmaxis' future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Pharmaxis as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

Program

11.00	Welcome and introduction to program	Michael Woods
11.05	Introduction to Pharmaxis research and clinical development program	Dr Wolfgang Jarolimek Gary Phillips
11.15	The myelofibrosis landscape and MF-101	Dr Gabriela Hobbs (Massachusetts General Hospital)
11.45	Hepatocellular cancer and Rochester University investigator led study	Dr Paul Burchard (Rochester NY)
12.15	Pancreatic Cancer	Dr Tom Cox (Garvan Sydney)
12.40	Pharmaxis Q&A	Gary Phillips
13.00	Close

Pharmaxis' portfolio of compounds in research and development

Pharmaxis is the global leader in lysyl oxidase chemistry and biology

Multi year research program leveraged with extensive scientific collaborations worldwide has delivered 2 drugs in the clinic

Lysyl oxidases are the final stage in fibrosis

Tissue stiffening due to increases in collagen and number of cross-links is preventable through lysyl oxidase inhibition and at the heart of a true anti-fibrotic therapy

•  PXS-5505

  • - Oral dosage form - twice a day dosing

  • - Patent 2018

  • - Strong pre clinical evidence in models of fibrosis and cancer

  • - INDs approved for myelofibrosis and hepatocellular carcinoma

  • - Potential in multiple cancer indications

  • - Phase 1 data demonstrates a safe, well tolerated drug that gives >90% inhibition of LOX enzymes

•  PXS-6302

  • - Topical dosage form - one application per day

  • - Patent 2019

  • - Strong pre clinical evidence in models of skin fibrosis and scarring

  • - Potential in prevention of scar formation and modification of existing scars

  • - Phase 1 data demonstrates a safe, well tolerated drug that gives full inhibition of LOX enzymes in the skin with minimal systemic exposure